Clene’s CNM-Au8 Shows Promise in ALS Treatment, Projecting Significant Stock Upside
Clene's CNM-Au8 shows promise in ALS treatment, leading analyst Joseph Pantginis to maintain a Buy rating with a $31 target, projecting a 50-65% stock increase post-FDA meeting in 2026. Positive biomarker results enhance investor confidence.
Clene, the Consumer Defensive sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on the stock and has a $31.00 price target.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Joseph Pantginis’s rating is based on the promising results from Clene’s CNM-Au8 ALS biomarker analyses, which have shown statistically significant reductions in disease-relevant biomarkers. These results, particularly the decreases in NfL and GFAP levels, correlate strongly with longer survival rates in ALS patients. This compelling evidence not only validates the initial HEALEY ALS platform trial results but also addresses previous concerns raised by the FDA.
Furthermore, Pantginis anticipates substantial upside potential for Clene’s stock, projecting a 50-65% increase following a Type C meeting with the FDA in the first quarter of 2026. This meeting is expected to support the submission of a New Drug Application (NDA) via the accelerated approval pathway. The positive data and strategic alignment with the FDA position CNM-Au8 well for regulatory approval, enhancing investor confidence in Clene’s future prospects.
In another report released on November 20, Benchmark Co. also maintained a Buy rating on the stock with a $31.00 price target.
